临床表现和治疗低质左心综合征的临床表现和治疗
Nikolaus A Haas1, David J Driscoll2, Silke Rickert-Sperling3
1Department of Pediatric Cardiology and Intensive Care, Ludwig Maximilians University, Munich, Germany. Nikolaus.haas@med.uni-muenchen.de.
Advances in experimental medicine and biology
|June 17, 2024
概括
低发性左心综合征 (HLHS) 是一种严重的先天性心脏缺陷,心脏左侧发育不良. 这种疾病会影响左心室和大动脉,影响血液流动,需要专门的医疗护理.
科学领域:
- 心脏病学 心脏病学
- 儿童心脏病学 儿童心脏病学
- 遗传性心脏病研究 遗传性心脏病研究
背景情况:
- 缺血性左心综合征 (HLHS) 是一种严重的先天性心脏缺陷.
- 其特点是左心室发育不良和上升性大动脉,导致逆行性输液.
- 相关异常包括大动脉和心心膜缩/缩小,心室隔膜缺陷和大动脉缩.
研究的目的:
- 提供对HLHS复杂解剖和生理特征的全面概述.
- 要突出与HLHS相关的心脏形的频谱.
- 作为理解儿科心脏病中的HLHS的基础资源.
主要方法:
- 审查现有的文学和病例研究关于低质左心综合征.
- 分析解剖变异及其对心脏功能的影响.
- 诊断标准和相关条件的综合.
主要成果:
- 高低血压关症涉及左心室和上升大动脉的严重低血压.
- 大动脉和 mitra 门异常,以及心房间隔膜缺陷是常见的.
- 同时存在的条件,如异常的肺静脉排水和主动脉缩经常发生.
结论:
- HLHS呈现了一系列复杂的心脏形.
- 了解这些变异对于诊断和管理至关重要.
- 进一步研究HLHS病理生理学和治疗是有必要的.
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
197
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
197
Pulmonary Hypertension: Classification and Pathogenesis
168
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
168
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157


